LeadIQ logo
Learn more at LeadIQ.com

Insights

Late-stageOpportunity Orphazyme maintains a late-stage drug pipeline focused on neurodegenerative orphan diseases, indicating potential for strategic partnerships or licensing deals, especially with organizations seeking scalable rare-disease therapies.

GlobalExpansion With a footprint across Denmark, Switzerland and a US headquarters in Chicago, there are clear regional expansion and co-development opportunities, including collaboration with US-based biotechs and contract manufacturing or regional access agreements.

AccessLiquidity Significant funding history ($262M) alongside an asset divestiture in 2022 suggests capacity for structured financing, milestone-based partnerships, or collaboration models that reduce upfront risk while unlocking Orphazyme’s pipeline potential.

StrategicPivot The asset sale to Zevra/KemPharm and CEO leadership changes imply a strategic pivot toward rare disease commercialization; sales discussions could focus on asset-backed collaborations, royalty deals, or co-commercialization in niche indications.

TechReady The company’s web technology stack (Drupal, WordPress, Cloud infrastructure) signals a modern digital presence that can support partner-facing portals, investor communications, and streamlined licensing or collaboration offer materials.

Similar companies to Orphazyme A/S

Orphazyme A/S Tech Stack

Orphazyme A/S uses 8 technology products and services including Drupal, Joomla, Squarespace, and more. Explore Orphazyme A/S's tech stack below.

Media & News

Orphazyme A/S's Email Address Formats

Orphazyme A/S uses at least 2 email formats:
Orphazyme A/S Email FormatsExamplePercentage
First.Last@orphazyme.comJohn.Doe@orphazyme.com
90%
Last@orphazyme.comDoe@orphazyme.com
10%

Frequently Asked Questions

What is Orphazyme A/S's phone number?

Minus sign iconPlus sign icon You can contact Orphazyme A/S's main corporate office by phone at
+45-70-70-2****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Orphazyme A/S's stock symbol?

Minus sign iconPlus sign iconOrphazyme A/S is a publicly traded company; the company's stock symbol is ORPHY.

What is Orphazyme A/S's official website and social media links?

Minus sign iconPlus sign iconOrphazyme A/S's official website is orphazyme.com and has social profiles on LinkedIn.

How much revenue does Orphazyme A/S generate?

Minus sign iconPlus sign icon As of July 2026, Orphazyme A/S's annual revenue is estimated to be <$1M.

What is Orphazyme A/S's SIC code and NAICS code?

Minus sign iconPlus sign iconOrphazyme A/S's SIC code is 8733 - Noncommercial Research Organizations and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Orphazyme A/S have currently?

Minus sign iconPlus sign iconAs of July 2026, Orphazyme A/S has approximately 108 employees across 2 continents, including Europe and North America. Key team members include Executive Director, Payer Engagement: T. D., Senior Scientist: R. M. and Statistics Specialist: T. H. Explore Orphazyme A/S's employee directory with LeadIQ.

What industry does Orphazyme A/S belong to?

Minus sign iconPlus sign iconOrphazyme A/S operates in the Biotechnology industry.

What technology does Orphazyme A/S use?

Minus sign iconPlus sign iconOrphazyme A/S's tech stack includes Drupal, Joomla, Squarespace, WordPress, Google Cloud, WP Engine, PHP and MediaElement.js.

What is Orphazyme A/S's email format?

Minus sign iconPlus sign iconOrphazyme A/S's email format typically follows the pattern of First.Last@orphazyme.com. Find more Orphazyme A/S email formats with LeadIQ.

How much funding has Orphazyme A/S raised to date?

Minus sign iconPlus sign icon As of July 2026, Orphazyme A/S has raised $262M in funding. The last funding round occurred on Feb 07, 2020 for $109M.

When was Orphazyme A/S founded?

Minus sign iconPlus sign iconOrphazyme A/S was founded in 2009.
Orphazyme A/S logo

Orphazyme A/S

BiotechnologyDenmark51-200 Employees

Orphazyme A/S is a global biopharmaceutical company based in Denmark that concentrates on developing therapies for neurodegenerative orphan diseases. It maintains a late-stage drug pipeline and aims to advance treatments that could meaningfully impact patients facing rare, serious conditions. The company is expanding its presence in the United States, including a Chicago-based headquarters, along with offices in Denmark and Switzerland. 

Operating within the biotechnology research sector, Orphazyme focuses on delivering therapies to a narrowly defined patient population with unmet medical needs. It is publicly traded on Nasdaq Copenhagen and Nasdaq U.S., reflecting its status as an international firm with cross-border operations.

Section iconCompany Overview

Phone number
+45-70-70-2****
Website
orphazyme.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ORPHY
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $262M

    Orphazyme A/S has raised a total of $262M of funding over 7 rounds. Their latest funding round was raised on Feb 07, 2020 in the amount of $109M as a Post IPO Equity.

  • <$1M

    Orphazyme A/S's revenue is estimated to be in the range of <$1M

Company Leadership

  • Executive Director, Payer Engagement at Orphazyme A/S
    T. D.
    Executive Director, Payer Engagement
    Mobile Phone
  • Senior Scientist at Orphazyme A/S
    R. M.
    Senior Scientist
    Mobile Phone
  • Statistics Specialist at Orphazyme A/S
    T. H.
    Statistics Specialist
    Mobile Phone
  • Employee at Orphazyme A/S
    K. S.
    Mobile Phone
  • Employee at Orphazyme A/S
    K. M.
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.